Research programme: small molecule drugs - Astex/Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: small molecule drugs - Astex/Bayer HealthCare Pharmaceuticals

Latest Information Update: 25 Jul 2011

Price : $50

At a glance

  • Originator Astex Therapeutics; Bayer Schering Pharma
  • Developer Astex Therapeutics; Bayer HealthCare Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 26 Mar 2010 Preclinical development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top